# Haploidentical HCT for Severe Aplastic Anemia

> **NCT04558736** · PHASE2 · RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Aplastic Anemia
- Bone Marrow Failure Syndrome

## Interventions

- **DRUG:** Anti-Thymocyte Globulin (Rabbit)
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Mesna
- **DRUG:** G-CSF
- **RADIATION:** Total Lymphoid Irradiation (TLI)
- **DEVICE:** CliniMACS
- **BIOLOGICAL:** HPC, A Infusion
- **BIOLOGICAL:** CD45RA-depleted DLI

## Key facts

- **NCT ID:** NCT04558736
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-21
- **Primary completion:** 2029-07-01
- **Final completion:** 2030-07-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04558736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04558736, "Haploidentical HCT for Severe Aplastic Anemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04558736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*